HAEMONETICS CORP

This summary highlights selected information in this proxy statement (this "Proxy Statement"), which is being furnished in connection with the solicitation of proxies by Haemonetics Corporation for use at the 2026 Annual Meeting of Shareholders. Please review this entire Proxy Statement before voting. References in this Proxy Statement to "Haemonetics," the "Company," "we," "us" or "our" refer to Haemonetics Corporation.

Voting Roadmap

2026 ANNUAL MEETING OF SHAREHOLDERS

MEETING AGENDA AND VOTING RECOMMENDATIONS

HOW TO VOTE

HAEMONETICS CORPORATION | 2026 Proxy Statement 3

Performance Highlights

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. We view our operations and manage our business in three principal reporting segments: Plasma, Blood Center and Hospital. The Company’s common stock trades on the New York Stock Exchange ("NYSE") under the symbol "HAE."

Haemonetics delivered strong fiscal 2026 performance, reflecting disciplined execution, strategic innovation and strengthened leadership. We met or exceeded nearly all of ourtotal company financial targets for fiscal year 2026 despite revenue growth headwinds from prior-year portfolio transitions—including the sale of our Whole Blood product line and wind-down of our CSL Plasma U.S. supply agreement—that together represented approximately $153 million of nonrecurring fiscal 2025 revenue. Our Plasma and TEG® product lines drove fiscal 2026 organic growth through sustained share gains, innovation-based pricing and durable end-market demand, demonstrating the strength and resilience of these core products and our increasingly productive operating model. In Interventional Technologies, we addressed near-term challenges driven by competitive dynamics and evolving electrophysiology trends through targeted commercial measures and operational improvements, positioning the portfolio for a return to growth in future periods. During fiscal 2026, we also completed key organic and inorganic initiatives that position us well for continued market leadership in our Plasma and Vascular Closure product lines, specifically: (i) FDA 510(k) clearance for NexSys PCS® with Persona® PLUS technology in Plasma and (ii) FDA approval of expanded labeling for the VASCADE® MVP XL venous vascular closure system and the acquisition of Vivasure Medical in Vascular Closure. The addition of Frank Chan as Chief Operating Officer and the promotion of Roy Galvin to Chief Commercial Officer further strengthened our leadership team and streamlined our commercial and operational capabilities. Haemonetics’ fiscal 2026 year-end also marked the successful completion of our four-year long-range plan, during which we built a more diversified, sustainable and durable business and delivered strong results against ambitious multi-year goals. Looking ahead to fiscal 2027, we remain focused on creating long-term value for shareholders through expanded market share, continued innovation and sustained growth across our core products.

For further discussion of our fiscal 2026 business highlights and how our fiscal 2026 performance affected our Named Executive Officers' compensation, please see our Compensation Discussion and Analysis beginning on page 22. For additional information on our fiscal 2026 financial results please see our Annual Report on Form 10-K for the fiscal year ended March 28, 2026.

Governance Highlights

Charles J. Dockendorff has determined to retire from the Board of Directors (the "Board") of Haemonetics Corporation following the completion of his current term in July 2026. Accordingly, the following "Governance Highlights" are for the eight continuing Board members nominated for re-election at our 2026 Annual Meeting of Shareholders, all of whom (with the exception of Christopher A. Simon, our President and Chief Executive Officer) are independent.

BOARD COMPOSITION SNAPSHOT

4 HAEMONETICS CORPORATION | 2026 Proxy Statement

BOARD MEMBERS

Committee Chair

INDEPENDENT DIRECTOR QUALIFICATIONS

As discussed below under “Board Composition and the Director Nomination Process” (beginning on page 9), the Governance and Compliance Committee is responsible for reviewing and assessing the appropriate skills, experience and backgrounds that should be reflected in the composition of the Board. The experience, expertise and diversity represented by the Board as a collective body allow the Board to lead Haemonetics in a manner that serves its shareholders’ interests appropriately. The Governance and Compliance Committee believes that the independent directors on our Board have an effective mix of experience, qualifications, attributes and skills that are important to our business, which include:

CEO or direct profit and

loss accountability

Accountability for medical affairs or

relevant clinical or R&D activities

Responsibility for product development,

innovation and technology

Responsibility or accountability

for enterprise risk management

Other public company

board experience

Responsibility for

operational effectiveness

Experience in financial

compliance and reporting

Responsibility for corporate

strategic planning or major output

Mergers and acquisitions experience

HAEMONETICS CORPORATION | 2026 Proxy Statement 5

BOARD REFRESHMENT

The Board does not endorse arbitrary term limits for director service, nor does it believe in automatic re-nomination until directors reach a mandatory retirement age. The Board and each committee of the Board conduct an annual self-evaluation of their performance, which is an important determinant for Board refreshment. Director feedback solicited from the formal self-evaluation process is discussed during Board and committee meetings and, where appropriate, addressed with management. The Board’s annual self-evaluation process also includes an individual Board member peer review component. The director peer review process was facilitated by our Board Chair in fiscal 2026 with feedback provided to each individual director.

As provided in the Company’s Principles of Corporate Governance, directors generally will not be nominated for re-election at any annual meeting of shareholders following their 75th birthday. The Board determined to waive the Company’s director retirement age guideline with respect to Ellen Zane in connection with her nomination for reelection at the Company’s 2026 Annual Meeting of Shareholders. Ms. Zane will turn 75 shortly before the Company’s 2026 Annual Meeting of Shareholders. In reaching this determination, the Board considered Ms. Zane’s significant experience, deep knowledge of the Company’s business and strategy, and continued meaningful contributions as Board Chair and Chair of the Governance and Compliance Committee. The Board also considered the importance of continuity and stability in Board leadership as part of its ongoing succession planning and Board refreshment efforts. The Board believes Ms. Zane’s continued service as Board Chair will support an orderly leadership transition through continuity and mentorship of potential successors and reflects the Board’s judgment that her continued service is in the best interests of the Company and its shareholders. As part of our fiscal 2026 shareholder outreach efforts (see “Shareholder Outreach” on page 7), we discussed the Board’s prospective waiver and rationale with shareholders, who generally supported the Board’s determination provided the Board believed the waiver was in the best interests of the Company and its shareholders and the Company provided clear disclosure regarding the Board’s rationale for the waiver in this proxy statement.

To further promote refreshment, and as an alternative to term limits, the Principles of Corporate Governance also provide that the Board will seek to maintain anaverage tenure of 10 years or less for its independent Board members as a group (see "Board Composition Snapshot" on page 4 for the current average tenure of our independent Board members). The Board maintains discretion in each case to waive these guidelines for a director if it deems such waiver to be in the best interests of the Company.

How We Think About Board Refreshment

BEST PRACTICES

We are committed to high standards in corporate governance and creating a corporate governance environment that supports the long-term success of our Company. Our governance practices include the following:

6 HAEMONETICS CORPORATION | 2026 Proxy Statement

SHAREHOLDER OUTREACH

The Company is committed to transparent and active engagement with its shareholders. On an ongoing basis, members of senior management meet with shareholders to discuss the Company’s business fundamentals, performance and long-term outlook. Our Board also proactively engages with shareholders on governance and executive compensation matters and other topics of shareholder interest. During the fall and winter of fiscal 2026, our Board Chair (who also Chairs our Governance and Compliance Committee) and our Compensation Committee Chair offered meetings to shareholders that collectively held nearly 50% of our shares outstanding. Together with members of our Legal and Investor Relations teams, these Board members met in the fourth quarter of fiscal 2026 with shareholders representing over 36% of shares outstanding to discuss, among other topics, Haemonetics' corporate strategy and performance, board composition and refreshment, executive compensation, corporate responsibility and other governance matters. Details of shareholder feedback are discussed throughout this Proxy Statement.

For information on how to contact our Board please see "Communications with the Board of Directors" on page 14.

CORPORATE RESPONSIBILITY

At Haemonetics, our corporate responsibility programs and practices inform our corporate strategy and support our Purpose as we challenge ourselves to drive greater possibilities and meaningfully advance healthcare. How we do this work is equally important.

We are committed to taking the necessary steps across all parts of our business to ensure the long-term health and success of our Company, our colleagues, our customers and our communities. Haemonetics’ corporate responsibility framework augments our corporate strategy by proactively identifying and managing the environmental, social and governance risks and opportunities relevant to our Company and those we serve across four sustainability pillars, as represented in the graphic below:

For more information, please see our 2024-2025 Corporate Responsibility Report available on our website at www.haemonetics.com. The 2024-2025 Corporate Responsibility Report and other information on our website are not incorporated by reference into, and do not form any part of, this Proxy Statement.

HAEMONETICS CORPORATION | 2026 Proxy Statement 7

Performance Highlights

ELEMENTS OF TOTAL COMPENSATION

When setting compensation for our Named Executive Officers, or NEOs, the Compensation Committee focuses on total direct compensation. Total direct compensation includes three major components – base salary, annual short-term incentive compensation and annual long-term incentive compensation – all of which are designed to work together to drive a complementary set of behaviors and outcomes. The following chart illustrates, for fiscal 2026, the target annual compensation mix among the three elements of direct compensation for our Chief Executive Officer and, on average, for our other NEOs. For more information, see "Target Annual Compensation Mix" on page 28.

(1)Long-term incentive compensation reflects grant value of fiscal 2026 annual long-term incentive awards granted to our Named Executive Officers. For more information, see "Individual Fiscal 2026 Long-Term Incentive Awards" beginning on page 32.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this Proxy Statement that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this Proxy Statement may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the Company’s strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company's share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Factors that may cause actual results to differ materially from those contemplated by the statements in this Proxy Statement can be found in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended March 28, 2026 under the headings "Cautionary Statement Regarding Forward-Looking Information" and "Risk Factors" and in our other filings with the Securities and Exchange Commission ("SEC"). The Company does not undertake to update these forward-looking statements.

This Proxy Statement contains statements regarding individual and Company performance objectives and targets. These objectives and targets are disclosed in the limited context of our compensation plans and programs and should not be understood to be statements of management’s future expectations or estimates of future results or other guidance. We specifically caution investors not to apply these statements to other contexts.

8 HAEMONETICS CORPORATION | 2026 Proxy Statement